BANGALORE, Aug 12 (Reuters) - Sun Pharmaceutical Industries (SUN.BO) has got the U.S. Food and Drug Administration’s approval to launch its generic version of GlaxoSmithKline’s (GSK.L) Imitrex tablets to treat migraine, the Indian drugmaker said.
Sun Pharma, India’s largest drugmaker by market value, has also received U.S. regulatory approval to launch oxaliplatin injections, the copycat version of Sanofi-Aventis’ (SASY.PA) Eloxatin that is used to treat colon and rectal cancer, it informed the Bombay Stock Exchange on Wednesday.
Sun Pharma will share a 180-day marketing exclusivity for oxaliplatin with three other generic makers, the Indian firm said.
Oxaliplatin injections have annual sales of about $2.3 billion in the United States. (Reporting by Sumeet Chatterjee; Editing by Himani Sarkar)